NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Lee S, Coleman CI, Limone B, et al. Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov. (Comparative Effectiveness Reviews, No. 85.)

Cover of Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis

Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis [Internet].

Show details

Appendix FEvidence Tables

Table 5. Final health outcomes (1) (MS Word, 65K)

Table 6. Final health outcomes (2) (MS Word, 67K)

Table 7. Intermediate health outcomes (1) (MS Word, 67K)

Table 8. Intermediate health outcomes (2) (MS Word, 67K)

Table 9. Adverse outcomes (1) (MS Word, 65K)

Table 10. Adverse outcomes (2) (MS Word, 65K)

Table 11. Adverse outcomes (3) (MS Word, 65K)

References for Evidence Tables

Saurat JH, Stingl G, Dubertret L, et al. for the CHAMPION Study Investigators. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) Br J Dermatol. 2008;158:558–66. [PubMed: 18047523]
Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) Br J Dermatol. 2011;165:1109–17. [PubMed: 21910713]
Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009;29:210–214. [PubMed: 18763027]
Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol. 2008;158:1345–1349. [PubMed: 18410408]
Inzinger M, Heschl B, Weger W, et al. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry. J Invest Dermatol. 2011;165:640–5. [PubMed: 21564068]
Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2008;22:341–344. [PubMed: 18005022]
Garavaglia MC, Altomare G. Etanercept therapy in patients with psoriasis and concomitant HCV infection. Int J Immunopathol Pharmacol. 2010;23:965–969. [PubMed: 20943071]
Strober BE, Poulin Y, Kerdel FA, et al. Switching to adalimumab for psoriasis patients with a suboptimal response to etanercept, methotrexate, or phototherapy: efficacy and safety results from an open-label study. J Am Acad Dermatol. 2011;64:671–681. [PubMed: 21414495]
Magliocco MA, Lozano AM, Van Saders C, Schuler KW, Gottlieb AB. An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept. J Drugs Dermatol. 2007;6:424–427. [PubMed: 17668540]
Mazzotta A, Esposito M, Costanzo A, Chimenti S. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol. 2009;10:319–324. [PubMed: 19658444]
Costanzo A, Mazzotta A, Papoutsaki M, Nistico S, Chimenti S. Safety and efficacy study on etanercept in patients with plaque psoriasis. Br J Dermatol. 2005;152:187–189. [PubMed: 15656833]
Bansback N, Sizto S, Sun H, et al. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009;219:209–18. [PubMed: 19657180]
Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008;158:549–557. [PubMed: 18047521]
Saurat JH, Langley R, Sting G, Mcllrait M. Adalimumab treatment is associated with more rapid improvement in psoriasis versus methotrexate and versus placebo: results from the CHAMPION study. Br J Dermatol. 2007;157:S1–S9.
Mrowietz U, Gu Y, Okun M, Luger T. Methotrexate-treated psoriasis patients transitioning to adalimumab: Efficacy and safety outcomes. J Am Acad Dermatol. 2008 Feb:2609. AB120.
Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy. [Accessed Apr. 16, 2012]. Available at: http:​//clinicaltrials​.gov/ct2/show/NCT00566722.
The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis. [Accessed Apr. 16, 2012]. Available at: http:​//clinicaltrials​.gov/ct2/show/NCT00251641.
Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis. [Accessed Jul. 1, 2012]. Available at: http://www​.clinicaltrials​.gov/ct2/show/NCT00936065.
Emerit I, Antunes J, Silva JM, Freitas J, Pinheiro T, Filipe P. Clastogenic plasma factors in psoriasis--comparison of phototherapy and anti-TNF-α treatments. Photochem Photobiol. 2011;87:1427–32. [PubMed: 21824151]
Gelfand JM, Wan J, Callis Duffin K, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. Arch Dermatol. 2012;148:487–94. [PMC free article: PMC3476943] [PubMed: 22508874]
PubReader format: click here to try


  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.4M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...